China Approves HERNEXEOS for Lung Cancer Treatment

Key Takeaways

• NMPA conditional approval covers adults with unresectable, locally advanced or metastatic NSCLC with activating HER2 (ERBB2) TKD mutations as initial treatment.
• Supporting data cited: 75.7% objective response rate in treatment-naïve Beamion LUNG-1 patients; full approval needs confirmatory benefit.
• FDA accelerated approval for Hernexeos expanded on February 26, 2026 under the National Priority Voucher pilot after an August 2025 prior-therapy approval.
• HERNEXEOS is an oral irreversible HER2 TKI; it is not a broad lung-cancer approval beyond the labeled mutation-defined populations.

What exactly did China approve for HERNEXEOS?

Boehringer Ingelheim announced that China’s National Medical Products Administration conditionally approved HERNEXEOS (zongertinib tablets) as monotherapy for adult patients with unresectable, locally advanced or metastatic NSCLC whose tumors have activating HER2 (ERBB2) tyrosine kinase domain mutations, for use at initial diagnosis. The company said full approval depends on confirmation of clinical benefit in an ongoing trial.

Source: GlobeNewswire — China HERNEXEOS approval.

What Beamion LUNG-1 results supported the decision?

The China approval communication cites Phase Ib Beamion LUNG-1 data showing a 75.7% objective response rate in treatment-naïve patients. The company also notes prior China approval for previously treated patients and Breakthrough Therapy Designation from China’s CDE for first-line use.

• Drug: HERNEXEOS (zongertinib)
• Class: irreversible HER2-selective TKI
• ORR cited (treatment-naïve): 75.7%
• Approval type in China: conditional

How does the U.S. FDA status compare?

FDA granted accelerated approval to zongertinib for HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy on August 8, 2025, and expanded accelerated approval on February 26, 2026 under the Commissioner’s National Priority Voucher pilot to include patients who have not received prior therapy, according to FDA announcements.

Primary: FDA — Hernexeos National Priority Voucher approval.

Detail: FDA — zongertinib accelerated approval.

What should oncology BD and access teams watch next?

Track confirmatory Beamion Phase 3 readouts (LUNG-2/LUNG-3 as described by the sponsor), companion diagnostic availability, and China reimbursement timing after conditional approval. U.S. accelerated approval likewise remains contingent on confirmatory evidence. Competitive maps should include other HER2-mutant NSCLC approaches, not only TKIs.

Commercial teams should also separate Hong Kong and Japan approvals mentioned by the sponsor from the Mainland China conditional label when building access forecasts.

What remains unproven?

Conditional and accelerated approvals do not equal traditional full approval. Public primaries cited here do not establish overall survival superiority versus chemotherapy or immunotherapy combinations in first-line Phase 3. Do not generalize the 75.7% ORR beyond the Beamion LUNG-1 treatment-naïve cohort described by the sponsor.

Related NovaPharma coverage

• China’s rise in drug development and U.S. oncology
• Chinese Pharma Global Deals
• FDA approves Vyloy for HER2-negative gastric cancer

Frequently Asked Questions

Primary Sources

1. GlobeNewswire — China HERNEXEOS approval
2. FDA — Hernexeos National Priority Voucher approval
3. FDA — zongertinib accelerated approval